|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects 显示文摘 | Stass H Dalhoff A Kubitza D | 1998 | Antimicrob Agents Chemother1998，42，8： | 1 |
| 2 | Rivaroxaban( BAY 59-7939) an oral direct factor Xa inhibitor has nolinically relevant interaction with naproxen 显示文摘 | Kubitza D Michaell B Wolfgang M | 2007 | Br J Clin Pharm2007，4，63： | 1 |
| 3 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7959 ) in heahhy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 4 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor显示文摘 | Kubitza D Becka M Voith B | | 0，，： | 1 |
| 5 | Safety, tolerability, phar- macodynamics, and pharmacokinetics of rivaroxaban-an oral, di- rect Factor Xa inhibitor-are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 6 | Metabolism and excretion of rivaroxaban,an oral,direct factor Xa inhibitor,in rats,dogs,and humans显示文摘 | Weinz C Schwarz T Kubitza D | | 0，，： | 1 |
| 7 | Pharmacokinetics of moxifloxacin, a novel 8- methoxy- quinolone, in patients with renal dysfunction显示文摘 | STASS H KUBITZA D HALABI A et ol | 2002 | Br J Clin Pharmacol2002，53，3： | 1 |
| 8 | No interaction between the novel oral direct factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Phann2006，46，3： | 1 |
| 9 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral direct factor Xa inhibitor in healthy subjects显示文摘 | Mueck W Beeka M Kubitza D | | 0，，： | 1 |
| 10 | Preclinical and clinical characteristics of rivarraxaban:a novel,oral,direct factor Xa inhibitor显示文摘 | Laux V Perzborn E Kubitza D | | 0，，： | 1 |
| 11 | Pharmacokinetics, safety,and tolerbility of ascending single doses of Moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects显示文摘 | Stass H Dalhoff A Kubitza D | 1998 | Antimicrob Agents Chemothe1998，42，8： | 1 |
| 12 | Pharmacokinetics, safety, and tolerability of ascending singledoses of moxifloxacin, a new 8-rnethoxyquinolone, administered to healthy subjects显示文摘 | Stass H Dalhoff A Kubitza D | 1998 | 42(8): 2060-20651998，42，8： | 1 |
| 13 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 14 | Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man显示文摘 | Stass H Kubitza D | 1999 | J Antimicrob Chemother1999，43，： | 1 |
| 15 | Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects显示文摘 | Stass H Dahloff A Kubitza D | 1998 | Antimicrob Agents Chemother1998，42，： | 1 |
| 16 | Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man显示文摘 | Stass H Kubitza D | 1999 | J Antimicrob Chemother1999，443，： | 1 |
| 17 | Safety, pharmaco- dynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor X a inhibitor--after multiple dosing in healthy male subjects 显示文摘 | Kubitza D Becka M Wensing G | 2005 | Eur J Clin Pharmacol2005，61，： | 1 |
| 18 | Safety, tolerabil- ity, pharmacodynamics, and pharmacokinetics of rivaroxa- ban--an oral, direct factor Xa inhibitor--are not affected by aspirin 显示文摘 | KUBITZA D BECKA M MUECK W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 19 | Pharmacokinetics,safety,and tolerability of ascending single doses of moxifloxacin,a new 8-me-thoxy guinolone,administered to healthy subjects显示文摘 | StassH Daihoff A Kubitza D | 1998 | Antimicrob Agents Chemother1998，42，： | 1 |
| 20 | Safety, pharmaco- dynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor X a inhibitor 显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员